Polyclonal Treg therapy is estimated at 43.0% by therapy type in 2026, with autologous Treg cells at 54.0% and autoimmune diseases at 42.0%. Adoption depends on stable suppressive function as individualized manufacturing and treatment scheduling limit wider clinical scale.
Treg Therapy Market Analysis By ApplicationTreg Therapy Market Analysis By Cell SourceTreg Therapy Market Analysis By End UserTreg Therapy Market Analysis By Target IndicationTreg Therapy Market Opportunity Matrix Growth Vs ValueTreg Therapy Market Breakdown By Therapy Type, Cell Source, And Region